109 related articles for article (PubMed ID: 27687793)
21. Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells.
Li X; Li B; Ni Z; Zhou P; Wang B; He J; Xiong H; Yang F; Wu Y; Lyu X; Zhang Y; Zeng Y; Lian J; He F
Mol Cancer Ther; 2017 Sep; 16(9):1806-1818. PubMed ID: 28533436
[TBL] [Abstract][Full Text] [Related]
22. Selenocysteine induces apoptosis in human glioma cells: evidence for TrxR1-targeted inhibition and signaling crosstalk.
Fan CD; Fu XY; Zhang ZY; Cao MZ; Sun JY; Yang MF; Fu XT; Zhao SJ; Shao LR; Zhang HF; Yang XY; Sun BL
Sci Rep; 2017 Jul; 7(1):6465. PubMed ID: 28743999
[TBL] [Abstract][Full Text] [Related]
23. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
[TBL] [Abstract][Full Text] [Related]
24. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
[TBL] [Abstract][Full Text] [Related]
25. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
[TBL] [Abstract][Full Text] [Related]
26. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
28. Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage.
Jokinen E; Koivunen JP
Int J Oncol; 2015 Sep; 47(3):1103-10. PubMed ID: 26135106
[TBL] [Abstract][Full Text] [Related]
29. Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo.
Karpel-Massler G; Shu C; Chau L; Banu M; Halatsch ME; Westhoff MA; Ramirez Y; Ross AH; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Jun; 6(16):14507-21. PubMed ID: 26008975
[TBL] [Abstract][Full Text] [Related]
30. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
Zoeller JJ; Vagodny A; Daniels VW; Taneja K; Tan BY; DeRose YS; Fujita M; Welm AL; Letai A; Leverson JD; Blot V; Bronson RT; Dillon DA; Brugge JS
Breast Cancer Res; 2020 Nov; 22(1):132. PubMed ID: 33256808
[TBL] [Abstract][Full Text] [Related]
31. Bcl-xL-inhibitory BH3 mimetic ABT-737 depletes platelet calcium stores.
Harper MT; Poole AW
Blood; 2012 May; 119(18):4337-8. PubMed ID: 22555663
[No Abstract] [Full Text] [Related]
32. Bcl-xL-inhibitory BH3 mimetics (ABT-737 or ABT-263) and the modulation of cytosolic calcium flux and platelet function.
Schoenwaelder SM; Jackson SP
Blood; 2012 Feb; 119(5):1320-1; author reply 1321-2. PubMed ID: 22308285
[No Abstract] [Full Text] [Related]
33. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
He Y; Zhang X; Chang J; Kim HN; Zhang P; Wang Y; Khan S; Liu X; Zhang X; Lv D; Song L; Li W; Thummuri D; Yuan Y; Wiegand JS; Ortiz YT; Budamagunta V; Elisseeff JH; Campisi J; Almeida M; Zheng G; Zhou D
Nat Commun; 2020 Apr; 11(1):1996. PubMed ID: 32332723
[TBL] [Abstract][Full Text] [Related]
34. Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.
Ren W; Joshi R; Mathew P
Mol Cancer Res; 2016 Dec; 14(12):1176-1181. PubMed ID: 27590631
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
[TBL] [Abstract][Full Text] [Related]
36. New agents that target senescent cells: the flavone, fisetin, and the BCL-X
Zhu Y; Doornebal EJ; Pirtskhalava T; Giorgadze N; Wentworth M; Fuhrmann-Stroissnigg H; Niedernhofer LJ; Robbins PD; Tchkonia T; Kirkland JL
Aging (Albany NY); 2017 Mar; 9(3):955-963. PubMed ID: 28273655
[TBL] [Abstract][Full Text] [Related]
37. Alkylphosphocholine-induced glioma cell death is BCL-X(L)-sensitive, caspase-independent and characterized by massive cytoplasmic vacuole formation.
Naumann U; Wischhusen J; Weit S; Rieger J; Wolburg H; Massing U; Weller M
Cell Death Differ; 2004 Dec; 11(12):1326-41. PubMed ID: 15389288
[TBL] [Abstract][Full Text] [Related]
38. CX3CR1 and malignant progression of glioma.
Lee S; Deneen B; Rao G
Aging (Albany NY); 2021 Sep; 13(17):20856-20857. PubMed ID: 34516407
[No Abstract] [Full Text] [Related]
39. EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-X
Inoue-Yamauchi A; Oda H
Biochem Biophys Res Commun; 2020 Jun; 526(3):612-617. PubMed ID: 32247610
[TBL] [Abstract][Full Text] [Related]
40. Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists.
Perez HL; Banfi P; Bertrand J; Cai ZW; Grebinski JW; Kim K; Lippy J; Modugno M; Naglich J; Schmidt RJ; Tebben A; Vianello P; Wei DD; Zhang L; Galvani A; Lombardo LJ; Borzilleri RM
Bioorg Med Chem Lett; 2012 Jun; 22(12):3946-50. PubMed ID: 22608961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
